ETM
ANIK icon

Euclidean Technologies Management’s Anika Therapeutics ANIK Stock Holding History

Euclidean Technologies Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-44,875
Closed -$1.83M – 96
2021
Q1 		$1.83M Hold
44,875
– – 1.59% 37
2020
Q4 		$2.03M Buy
44,875
+2,500
+6% +$94.9K 2.14% 15
2020
Q3 		$1.5M Hold
42,375
– – 1.89% 29
2020
Q2 		$1.6M Hold
42,375
– – 2.24% 8
2020
Q1 		$1.23M Buy
+42,375
New +$1.71M 2.02% 21

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Technologies Management's ANIK Position: Q2 2021 in Review

Euclidean Technologies Management sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 44,875 shares — an estimated $1.83M sold.

Euclidean Technologies Management first reported a position in ANIK in Q1 2020 and held it in 5 quarters. The position peaked at $2.03M in Q4 2020. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Euclidean Technologies Management reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 44,875 Anika Therapeutics shares in Q2 2021, an estimated $1.83M.
  • Euclidean Technologies Management first reported a position in Anika Therapeutics in Q1 2020 and held it in 5 quarters.
  • Euclidean Technologies Management's Anika Therapeutics position peaked at $2.03M in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Euclidean Technologies Management's 13F filing for Q2 2021, filed 5 Aug 2021.